Differentiated Visceral Fat Reduction in Early Trials of WVE-007
New clinical evidence shows meaningful visceral fat reduction with a single dose of an investigational therapy. A single 240 mg dose of WVE-007, an investigational INHBE GalNAc-siRNA (SpiNA design), produced continued placebo-adjusted reductions in visceral fat mass (−14.3%; p<0.05) and total fat mass (−5.3%), stabilization of lean mass (+2.4%), and clinically meaningful decreases in waist circumference (−3.3%) and body weight (−0.9%) at six-month follow-up in the Phase 1 portion of the INLIGHT trial.
Superior Visceral Fat Reduction Over Semaglutide
These improvements in the visceral fat-to-muscle ratio (−16.5% from baseline) exceeded the six-month effect observed with weekly 2.4 mg semaglutide (−12.2%) in the BELIEVE Phase 2 trial, despite substantially lower baseline body mass index (BMI ≈32 kg/m² versus ≈37 kg/m²) and lower visceral and subcutaneous fat in the INLIGHT population. The magnitude of visceral fat reduction with absolute lean-mass preservation represents a differentiated profile compared with current incretin-based therapies.
Durable Activin E Suppression Supports Infrequent Dosing
Durable, dose-dependent suppression of serum Activin E (maximum mean reduction up to 88%) was sustained through at least seven months, supporting potential once- or twice-yearly dosing. WVE-007 remained generally safe and well tolerated, with only mild or moderate treatment-emergent adverse events and no discontinuations.
Genetic Evidence Driving Targeted INHBE Silencing
Compelling human genetic data linking heterozygous loss-of-function variants in INHBE to lower visceral fat and reduced cardiometabolic risk provided the foundational rationale for this approach. WVE-007 leverages Wave Life Sciences’ Stereopure interfering Nucleic Acid (SpiNA) platform and GalNAc conjugation to silence INHBE mRNA in hepatocytes, lowering circulating Activin E and promoting selective lipolysis in adipocytes.
Phase 1 Trial Design and Key Analytical Methods
The Phase 1 single-ascending-dose portion of the INLIGHT trial enrolled otherwise healthy adults with overweight or obesity (mean BMI 32 kg/m² in the 240 mg cohort) in a randomized, placebo-controlled (3:1) design. Assessments included serial DEXA scans for body composition, anthropometric measures, and pharmacodynamic quantification of serum Activin E. A prespecified mixed-effects model for repeated measures confirmed dose-dependent and durable target engagement while isolating the statistically significant visceral fat reduction at the 240 mg dose.
Strategic Implications for Obesity and Cardiometabolic Care
The observed profile of meaningful visceral fat reduction, waist circumference improvement, and lean-mass preservation after a single dose carries important implications for health economics, market access, and long-term cardiometabolic management. The superior visceral fat-to-muscle ratio relative to semaglutide in a lower-BMI population, combined with the potential for infrequent dosing, could improve clinical outcomes while addressing payer and patient concerns around muscle loss and treatment burden.
The planned Phase 2a multidose component of INLIGHT, initiating in the second quarter of 2026, will provide further data on body weight, MRI-based body composition, liver fat, HbA1c, lipids, and muscle function over 12 months. These results could position WVE-007 as both a monotherapy and a maintenance therapy following incretin treatment, offering a new tool for sustainable weight management that preserves metabolic health.
